A research blog from the NCI Division of Cancer Prevention
Common Chemotherapy Drugs Seem to Increase Hearing Loss in Some Adults
September 27, 2022 | By Susan Jenks
More than half of cancer survivors who were treated with chemotherapy for the four most common types of cancer experienced clinically significant hearing loss and tinnitus after treatment, according to new research.
The surprise finding emerged from a cross-sectional study published recently in the British Medical Journal Supportive & Palliative Care involving 273 patients, mostly women, who received either platinum- or taxane-containing drug regimens alone, or in combination, for the treatment of lung, breast, gastrointestinal, or gynecologic cancers. Participants...
Samples from People With and Without Cancer Could Help Verify Future Blood Tests to Detect Cancer Early
September 15, 2022 | By Susan Jenks
Recruitment has begun for a clinical study that investigators hope will move “liquid biopsy” technology closer to its still-distant goal: a single blood test for the early detection of cancer. Collectively known as multi-cancer early detection (MCED) assays or sometimes multi-cancer detection assays (MCD), this new advancing technology is a promising concept for cancer screening, but there are key unanswered questions.
Research Highlights: Recently Published Studies on Compounds from Foods and Their Effect of Cancer Risk Measures
August 24, 2022 | By DCP Staff
Research Highlights are a new type of blog for Cancer Prevention Science, where recent publications are highlighted rather than a traditional news story.
This month’s blog post highlights how a cruciferous vegetable extract reduces toxins from tobacco and reports the effects of Polyphenon E in green tea on rectal aberrant crypt foci.
Researchers Seek to Care for the Whole Patient
August 10, 2022 | By Jack J. Lee, Ph.D.
In 2012, Patricia Ganz, M.D., saw a 39-year-old cancer survivor for a consultation who had a long-term history of anxiety during medical visits. The woman had been diagnosed with Hodgkin lymphoma when she was 23 years old. Though her treatment was successful, the cancer returned when she was 25. She received high-dose chemotherapy, a stem cell transplant, and full-dose radiation therapy to the chest. This treatment increased her risk for heart damage and breast cancer.
Dr. Ganz recommended continued monitoring for potential late medical effects, as well as psychosocial consultation...
Rising Endometrial Cancer Rates Spur New Approaches to Prevention
June 28, 2022 | By Jack J. Lee, Ph.D.
Unlike many other cancers, the incidence and death rates for uterine cancer are rising.
Rates of new uterine cancer cases have risen 0.6% per year from 2010-2019, and death rates have risen an average of 1.7% per year for the same time frame.
Over 90% of uterine cancers begin in the endometrium, the tissue lining the uterus. There are two main subtypes of endometrial cancer, endometrioid and nonendometrioid, and the subtypes are showing different trends, a recent NCI-led study found.
Large Studies Evaluating How to Personalize Breast Cancer Screening for All Women
May 6, 2022 | By DCP Staff
In the era of personalized medicine, prevention and screening for breast cancer are evolving toward new approaches that assess each woman’s risk and lifestyle factors.
All women do not carry the same risk for the same type of breast cancer. The old one-size-fits-all screening method can miss the most aggressive forms of the disease, or result in overdiagnosis of indolent disease.
How Precision Cancer Prevention Can Promote Health Equity
April 18, 2022 | By Jack J. Lee, Ph.D.
Overall, cancer death rates in the United States have been declining about 2% per year, current SEER data from 2014 through 2018 show. However, these improvements have not been experienced equally by everyone, which is one of the reasons that April is Minority Cancer Awareness Month, when we call attention to these disparities.
Engineering Synthetic Biomarkers for Early Detection of Cancers
February 9, 2022 | By Jack J. Lee, Ph.D.
Tumor cells release telltale molecules into blood, urine, and other bodily fluids. But it can be difficult to detect tumor-derived DNA, RNA, and proteins in the earliest stages of disease, when cancers can be easier to treat and cure. Earlier stages shed fewer cancer cells—and fewer tumor markers.
“Endogenous markers may be there, but not detectable with current technology,” said Sudhir Srivastava, Ph.D., M.P.H., chief of the Cancer Biomarkers Research Group in the NCI Division of Cancer Prevention. The clinical detection of tumors is limited to masses larger than roughly one...
Identifying New Biomarkers to Detect Lung Cancer Earlier
January 14, 2022 | By Jack J. Lee, Ph.D.
Lung cancer, the leading cause of cancer deaths worldwide killing 1.8 million people each year, is often diagnosed at an advanced stage when the chances for a cure are limited.
In the United States, almost 60% of people diagnosed with localized lung and bronchus cancer are likely to survive for 5 years. This is nearly 10 times more than those who are not diagnosed until their cancer has spread to distant parts of the body, who have a 5-year relative survival of 6.3%. Right now, more than half of lung cancers are diagnosed at this late state.
Ending Cancer as We Know It Is the Work of Many Capable Hands: A Moment to Say "Thank You"
December 20, 2021 | By Philip E. Castle, Ph.D., M.P.H.
Fifty years ago this week, the National Cancer Act was signed into law, kick-starting research that has changed how cancer is prevented, detected, diagnosed, treated, and survived, and moving us closer to a time when no one dies of cancer.
Starting in March of this year, we, the NCI Division of Cancer Prevention, honored the champions and changemakers of prevention, detection, and supportive care science, including those who focused on cancer health disparities in these areas. When we brainstormed who should be included among the individuals who gave years of their lives and work...